7.09

1.72% +0.12

Titan Pharmaceuticals, Inc. (de) (TTNP)

Overview News Price History Option Chain Discussions Forecast Stock Split

Titan Pharmaceuticals, Inc. (de) stock is currently priced at $7.09, with a 24-hour trading volume of 10,648. It has seen a +1.72% increased in the last 24 hours and a -1.97% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $6.96 pivot point. If it approaches the $7.16 resistance level, significant changes may occur.

Previous Close:

$6.97

Open:

$7.31

24h Volume:

10,648

Market Cap:

$6.48M

Revenue:

$61,000

Net Income/Loss:

$-6.17M

P/E Ratio:

-12.44

EPS:

-0.57

Net Cash Flow:

$-6.43M

1W Performance:

-3.14%

1M Performance:

-1.97%

6M Performance:

+1,527%

1Y Performance:

+792.96%

1D Range:

$6.75

$7.9964

52W Range:

$0.25

$9.29

Titan Pharmaceuticals, Inc. (de) Stock (TTNP) Company Profile

Name

Titan Pharmaceuticals, Inc. (de)

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

650 244 4990

Address

400 Oyster Point Boulevard, Suite 505, South San Francisco

Employee

Twitter

@titanpharma

Next Earnings Date

Latest SEC Filings

TTNP's Discussions on Twitter

Titan Pharmaceuticals, Inc. (de) Stock (TTNP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-26-19	Initiated	Maxim Group	Buy
Nov-10-17	Downgrade	ROTH Capital	Buy → Neutral

Titan Pharmaceuticals, Inc. (de) Stock (TTNP) Latest News

Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria

GlobeNewswire Inc.

Gold Moves Lower; Microbot Medical Shares Slide

Benzinga

Why Fisker Shares Are Trading Higher By Over 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Benzinga

Nasdaq Down Over 100 Points; Fortress Biotech Shares Plummet

Benzinga

Why Titan Pharmaceuticals Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

Benzinga

Titan Pharmaceuticals, Inc. (de) Stock (TTNP) Financials Data

Titan Pharmaceuticals, Inc. (de) (TTNP) Revenue 2024

TTNP reported a revenue (TTM) of $61.00 thousand for the quarter ending December 31, 2022, a -94.79% decline year-over-year.

Titan Pharmaceuticals, Inc. (de) (TTNP) Net Income 2024

TTNP net income (TTM) was -$6.17 million for the quarter ending September 30, 2023, a +39.44% increase year-over-year.

Titan Pharmaceuticals, Inc. (de) (TTNP) Cash Flow 2024

TTNP recorded a free cash flow (TTM) of -$6.42 million for the quarter ending September 30, 2023, a +16.40% increase year-over-year.

Titan Pharmaceuticals, Inc. (de) (TTNP) Earnings per Share 2024

TTNP earnings per share (TTM) was -$8.20 for the quarter ending September 30, 2023, a +52.33% growth year-over-year.

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.